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ABSTRACT
DESIGN OF DRUG DELIVERY STRATEGIES BASED ON WELL-
STIRRED VESSEL EXPERIMENTS
by
Kumud Kanneganti
Drugs are generally administered to the human body via injections (IV) or through other
paths such as the buccal, nasal routes. The main consideration when designing a
medication schedule is to maintain a therapeutic level of the drug in the body during the
course of treatment. To achieve this goal, when IV drug therapy is selected, particular
importance has to given to the dose to be injected and how to maintain the concentration
of the pharmaceutical active ingredient (API) in the body between a Minimum Toxic
Concentration (MTC) and a Minimum Effective Concentration (MEC). This therapeutic
range varies with the drug and is designed so that the patient takes full benefit of the
treatment while keeping potential risks or side effects to a minimum.
The aim of this thesis is to design drug administration protocols based on well-
stirred vessel experiments that mimic one- and two-compartment pharmacokinetic
models. A one-compartment model assumes that drug is evenly distributed in the body,
which is represented by a beaker with an inlet and an outlet stream. In a two-
compartment model, drug is distributed between the central and peripheral vessels. Only
bolus and constant-rate infusion are considered in this study. Mathematical models are
used to estimate the pharmacokinetic parameters and to derive administration strategies
to be tested experimentally. Results show that the well-stirred vessel captures the
behavior of one- and two-compartment models very well. The time-concentration profiles
of a tracer in the compartments are functions of the kinetic parameters.
DESIGN OF DRUG DELIVERY STRATEGIES BASED
ON WELL-STIRRED VESSEL EXPERIMENTS
by
Kumud Kanneganti
A Thesis
Submitted to the Faculty of
New Jersey Institute of Technology
in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Chemical Engineering
Otto H. York Department of
Chemical, Biological and Pharmaceutical Engineering
May 2010
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPROVAL PAGE
DESIGN OF DRUG DELIVERY STRATEGIES BASED
ON WELL-STIRRED VESSEL EXPERIMENTS
Kumud Kanneganti
Dr. Laurent Simon, Thesis Advisor 	 Date
Associate Professor, Otto H York Department of Chemical, Biological and
Pharmaceutical Engineering, NJIT.
Dr. Piero. M. Armenante, Committee Member
	 Date
Distinguished Professor, Otto H York Department of Chemical, Biological and
Pharmaceutical Engineering, NJIT.
Dr. Reginald. P. Tomkins, Committee Member
	 Date
Professor, Otto H York Department of Chemical, Biological and Pharmaceutical
Engineering, NJIT.
BIOGRAPHICAL SKETCH
Author:	 Kumud Kanneganti
Degree:	 Master of Science
Date:	 May 2010
Undergraduate and Graduate Education:
• Master of Science in Chemical Engineering,
New Jersey Institute of Technology, Newark, NJ, 2010
• Bachelor of Science in Chemical Engineering,
Nirma University, Ahmedabad, India, 2008
Major:	 Chemical Engineering
Publication:
Laurent Simon, Kumud Kanneganti and Kwang Seok Kim, Drug transport and
Pharmacokinetics for Chemical Engineering students. Chemical Engineer
Educator (To be published)
iv
To Mom and Dad, it is impossible to thank you for everything you've done,
from loving me unconditionally to raising me.
I am truly blessed to have the two of you in my life and could not have
asked for better role-models.
And
To God, for giving me strength when I needed it the most,
for giving me such wonderful and loving parents,
for giving me friends who stood by me through thick and thin,
and for giving me a good life.
ACKNOWLEDGMENT
I would like to take this opportunity to express my gratitude towards Dr. Laurent Simon,
Associate Professor, Otto H York Department of Chemical, Biological and
Pharmaceutical Engineering for providing me with an opportunity to work with him.
This not only gave me immense pleasure but also provided me with a platform to grow. I
would like to thank him for his guidance and invaluable advice throughout the course of
this study.
I am thankful to committee member, Dr. Piero M Armenante, Distinguished
Professor, Otto H York Department of Chemical, Biological and Pharmaceutical
Engineering for his timely advice and valuable inputs and a special thank you to Dr.
Reginald P Tomkins, Associate Chair, Otto H York Department of Chemical, Biological
and Pharmaceutical Engineering for his continuous encouragement throughout my stay at
NJIT. I would also like to thank Mr. Kwang Seok Kim for his timely help and finally my
family and friends for their unconditional love and support.
vi
TABLE OF CONTENTS
Chapter Page
1. INTRODUCTION 	 1
2. BACKGROUND 	 3
2.1 One-Compartment Model  3
2.1.1 IV Bolus  
	 ... 4
2.1.2 Multiple IV Boluses
	 5
2.1.3 Infusion 	 7
2.1.4 IV Boluses and Infusion 	 8
2.1.5 Experiments with One-Compartment model
	 8
2.2 Two-Compartment Model
	 11
2.2.1 IV Bolus 
	 ... 12
2.2.2 Multiple IV Boluses
	 15
2.2.3 Infusion 	 17
2.2.4 IV Boluses and Infusion
	 19
2.2.5 Experiments with Two-Compartment model
	 20
3. EXPERIMENTAL SECTION 	 23
3.1 Experiments on One-Compartment Model 	 23
3.1.1 Single IV Bolus 	 23
3.1.2 Multiple IV Boluses
	 24
3.1.3 Effect of Size of Dose and Dosage Interval
	 25
3.1.4 Effect of Time Dependent Kinetics  26
vii
TABLE OF CONTENTS
(Continued)
Chapter Page
3.1.5 Infusion 	 26
3.1.6 IV boluses and Infusion 	 27
3.2 Experiments on Two-Compartment Model 	 28
3.2.1 Single IV Bolus 	 28
3.2.2 Multiple IV Boluses 	 28
3.2.3 Effect of Time Dependent Kinetics 	 29
3.2.4 Infusion 	 30
3.2.5 IV Boluses and Infusion  30
4. RESULTS AND DISCUSSIONS 	 32
4.1 Experiments on One-Compartment Model 	 32
4.1.1 Single IV Bolus 	 32
4.1.2 Multiple IV Boluses 	 34
4.1.3 Effect of Size of Dose and Dosage Interval 	 36
4.1.4 Effect of Time Dependent Kinetics 	 39
4.1.5 Infusion 	 42
4.1.6 IV Boluses and Infusion 	 43
4.2 Experiments on Two-Compartment Model  45
4.2.1 Single IV Bolus 	 45
4.2.2 Multiple IV Boluses 	 47
4.2.3 Effect of Time Dependent Kinetics 	 49
viii
TABLE OF CONTENTS
(Continued)
Chapter	 Page
4.2.4 Infusion 	 53
4.2.5 IV Boluses and Infusion 	 54
5. CONCLUSION 	 55
5.1 Future Work 	 56
APPENDIX A MASS BALANCE EQUATIONS FOR EXPERIMENTAL 	 57
SETUP OF TWO-COMPARTMENT MODEL 	
APPENDIX B LAPLACE TRANSFORM METHOD 	 60
APPENDIX C DATA ANALYSIS  	 63
C.1 Data Analysis on One-compartment Model 	 63
C.2 Data Analysis on Two-compartment Model 	 63
APPENDIX D MATHEMATICA CODE FOR OPTIMIZATION 	 66
D.1 Mathematica Code for the Optimization of Multiple IV Bolus Regimes 	 66
D.2 Mathematica Code for the Optimization of IV Boluses with Infusion 	 69
REFERENCES 	 80
ix
LIST OF TABLES
Table	 Page
2.1 Calibration Table for Concentration versus Absorbance 	 11
x
LIST OF FIGURES
Figure	 Page
2.1
	
Representation of one-compartment model. 	
					
3
2.2 
	
Representation of the experimental setup for one-compartment model. 	
	
4
2.3 
	
Experimental setup of one-compartment model. 	
				
10
2.4 
	
Representation of two-compartment model. 	
					
12
2.5 
	
Representation of the experimental setup for two-compartment model.
	
	
13
2.6 
	
Experimental setup of two-compartment model. 	
				
22
4.1 
	
Plasma drug concentration-time profile for a single bolus dose. Loading dose is
	 33
0.04 g, kel = 0.028 second-1 . The symbols (♦) represent the experimental profile
and (■) represent the calculated profile.
4.2 
	
Plasma concentration profile due to one IV bolus (Nafcillin) : C 0p = 29.1 	 	33
μg/mL, kel = 0.483 hr-1.
4.3 
	
Plasma drug concentration time profile for a one compartment model with nine 	 34
IV Boluses. Loading dose is 0.04 g, kel = 0.028 second-1 , n = 9 and τ = 60
second. The symbols (♦) represent the experimental profile.
4.4 
	
Theoretically calculated plasma drug concentration time profile for one 35
compartment model with nine IV Boluses. Loading dose is 0.042 g, kel = 0.028
second-1 , n = 9 and τ = 60 sec. The symbols (■) represent the calculated profile.
4.5 
	
Plasma concentration profile for a multiple IV bolus regimen The parameters 35
for nafcillin, C0p  = 29.1 μg/mL and kel = 0.483 hr. '. For the simulation, n = 10
and τ = t1/2.
4.6 
	
Plasma drug concentration time profile for one compartment model with nine
	 37
IV Boluses with two drug sizes. Here, Dose # 1 is 0.073 g represented by (●)
and Dose # 2 is 0.109 g represented by (■), kel = 0.028 second- ' for both and τ =
45 seconds.
4.7 
	
Plasma drug concentration time profile for the change in dose interval. Dose # 1 38
= 0.073 g, kel = 0.028 second-1 for τ = 45 sec (●) and τ = 30 sec (■).
xi
LIST OF FIGURES
(Continued)
Figure	 Page
4.8 Plasma drug concentration time profile for the change in dose interval. Dose # 2
	 38
= 0.109 g, kel = 0.028 second-1 for τ = 45 sec (●) and τ = 30 sec (■).
4.9 Change of the rate constant of elimination during the length of the experiment.
	 39
4.10 The comparison between the plasma drug concentration time profiles with a
	 40
constant kel = 0.014minute-1 (●) and a plasma drug concentration time profile
with varyingel  (■). Loading dose = 0.169 g and τ = 45 min.
4.11 The symbols (♦) represent the experimental concentration profile forel  = 0.014
		
42
min-1
 and k0 = 5.6 g/min.
4.12 Calculated concentration profile is represented by the symbols (■) forel  =	 43
0.014 min-1 and0  = 5.6 g/min.
4.13 Plasma concentrations versus time for one IV bolus with infusion are
	 44
represented by (■), with loading dose of 0.4 g,el  = 0.014 min-1
 and k0
 = 5.6
g/min.
4.14 Plasma concentrations versus time for two (●) and four IV boluses (■) with
	 44
loading dose as 0.4 g andel = 0.014 min-1 followed by a constant-rate infusion
of k0 = 5.6 g/min.
4.15 Concentration profile for two-compartment model with initial dose 1.37 g. The
	 46
symbols (▲ ) and (■) represent the profile for the central and peripheral
compartment, respectively.
4.16 Calculated concentration profile for two compartment model, with a initial dose
	 46
of 1.37 g. The symbols (♦) and (■) represent the profile for the central and
peripheral compartment respectively.
4.17 Concentration profile for multiple boluses, with a loading dose of 0.82 g. The
	 48
first and second maintenance doses are 0.314 g and 0.252 g, respectively. The
kinetic rate constants are12  = 1.7999 hr-1 ,21  = 2.9246 hr-1 andel  = 0.2739 hr-
1. The symbols (♦) and (■) represent the profile for the central and peripheral
compartment respectively.
xii
LIST OF FIGURES
(Continued)
Figure
	 Page
4.18 Calculated concentration profile for multiple boluses, with loading dose of 0.82 
		
49
g. The first and second maintenance doses are 0.314 g and 0.252 g, respectively.
The kinetic rate constants are
k
12  = 1.7999 hf l ,21  = 2.9246 hr-1 andel
 =
0. 73  hr.
4.19 Concentration profile for one IV bolus of 1.37 g, where the symbols (♦) and 	
	
50
(▲) represent the profile for the central and peripheral compartment
respectively. The kinetic rate constants are k12 = 1.7993 hr,21  = 2.9246
and kel  = 0.2739 hr. Where as the symbols (■) and (X) represent the profile for
central and peripheral compartment, respectively. The kinetic rate constants are
k12
 = 1.4023 hr,21  = 2.9954 hr andel  = 0.2815 hr-I . The standard deviation
for ,21  ande l are 0.291, 0.617 and 0.098, respectively.
4.20 Concentration profile for one IV bolus of 1.37 g, the symbols (♦) and (▲) 	
	
51
represent the profile for the central and peripheral compartment respectively.
The kinetic rate constants as12
 = 1.7993 hr -1 ,21  = 2.9246 hr andel  = 0.2739
. Whereas the symbols (■) and (X) represent the profile for central and
peripheral compartment respectively. The kinetic rate constants as12  = 1.6915
, k21 = 3.7948 hr andel
 = 0.2794 hr.
4.21 Concentration profile for one IV bolus of 1.37 g, the symbols (•) and (▲)
 
	
52
represent the profile for the central and peripheral compartment respectively.
The kinetic rate constants as12  = 1.7993 hr, k21 = 2.9246 hr -1 andel  = 0.2739
. Whereas the symbols (■) and (X) represent the profile for central and
peripheral compartment respectively. The kinetic rate constants as12  = 1.6566
, k21 = 3.0903 hr andel
 = 0.4129 hr.
4.22 Concentration profile for IV infusion of 0.695 g of drug having an infusion rate 
		
53
R = 0.996 g/hr. The kinetic rate constants are12  = 1.0968 hr,21  = 2.3596
 and kel = 1.4335 hr. Here, the symbols (♦) represent the experimental profile
and (■) represents the calculated profile.
4.23 Concentration profile for three IV boluses with infusion of 0.695 g of drug with
	
	
54
a loading dose of 0.82 g. The first and second maintenance doses are 0.201 g
and 0.196 g respectively. The infusion rate was R = 0.996 g/hr. The kinetic rate
constants are12
 = 1.0968 hr, k21 = 2.3596 hr andl  = 1.4335 hr . The
symbols (♦) and (■) represent the profile for the central and peripheral
compartment, respectively.
CHAPTER 1
INTRODUCTION
Drugs are generally administered to the human body via injections (IV) or through other
paths such as the buccal and nasal routes. An injection (IV) used to administer the active
pharmaceutical ingredient (API) [1], introduces the API directly into the blood and hence
into the circulatory system, which distributes the drug throughout the body in a very short
time. This route also avoids the absorption process. When an API is administered,
absorption, distribution, metabolism and excretion, contribute towards the continuously
changing concentration of the drug in the body. Several tests can be carried out to study
the effects of these individual processes on the drug concentration. However, only
excretion is simulated in this study.
The objective of a drug therapy is to achieve and maintain an effective drug
concentration in the body. This is also the main consideration when designing a
medication schedule during the course of treatment. To achieve this goal, when IV drug
therapy is selected, particular importance has to given to the dose to be injected and how
to maintain the concentration of the API in the body between a Minimum Toxic
Concentration (MTC) and a Minimum Effective Concentration (MEC). This therapeutic
range varies with the drug and is designed so that the patient takes full benefit of the
treatment, while keeping potential risks or side effects to a minimum.
The drug absorption begins as soon as the drug is administered into the body. As a
result the medicament does not remain in a single location, but is distributed throughout
the body until it is totally removed. The various body locations to which a drug travels
1
2may be viewed as separate compartments, each containing some fraction of the
administered dose of the drug [2]. Each compartment is a specific organ or a site. Hence
the body is said to be a sum of all the compartments [3]. In this study, the body is
assumed to consist of one or two compartments.
The aim of this thesis is to design drug administration protocols based on well-
stirred vessel experiments that mimic one- and two-compartment pharmacokinetic
models. A one-compartment model assumes that the body is a single compartment and
that the drug is evenly distributed in the body, which is represented by a beaker with an
inlet and an outlet stream. A two-compartment model, on the other hand assumes that the
body is made of two compartments, namely, the blood and the tissue [2]. The drug is
distributed between the two chambers. In this description, the blood and tissue are
represented by the central and peripheral compartments, respectively. Time concentration
profiles are different in the two compartments. Only bolus and constant-rate infusion are
considered in this study. Mathematical models are used to estimate the pharmacokinetic
parameters and to derive administration strategies that are tested experimentally.
CHAPTER 2
BACKGROUND
2.1	 One-compartment Model
The one-compartment model is the simplest system that can be used to describe drug
distribution and elimination in the body. One-compartment model assumes that the
pharmaceutical enters and leaves the body, which acts like a single uniform chamber
represented in Figure 2.1.
Figure 2.1 Representation of one-compartment model.
In this framework, no distinction is drawn between the drug concentration in the
blood and the surrounding tissue. Hence, as soon as the active pharmaceutical ingredient
enters the body, it is instantaneously distributed throughout the volume.
Figure 2.2 shows the diagrammatic representation of the experimental setup used
to mimic the pharmacokinetics of a drug in one-compartment model. The equations
governing the process are derived using Figure 2.2 as a basis.
3
4Figure 2.2 Representation of the experimental setup for one-compartment model.
2.1.1 IV Bolus
An intravenous injection (IV bolus) ensures that a certain amount of drug is made
available in the system instantaneously. The kinetic model is derived by first noting that
the situation is similar to the addition of a rapid bolus dose to a Continuously Stirred
Tank Reactor (CSTR) or vessel (Figure 2.2). An outlet stream represents the drug
elimination.
The mass balance over the constant-volume system in Figure 2.2 gives a
differential equation:
Where kel is a first-order elimination rate constant (min -1), Cp is the concentration
of the drug in the plasma (g/L or g/mL) at corresponding time t (sec/min). The integration
of equation (1) gives:
5The elimination rate constant is calculated by plotting the concentration against
the time, Cp° is the drug concentration introduced in the distribution volume V (ml or L).
The amount drug in the system can be calculated if the elimination rate constant, the
volume of distribution and the amount of drug administered at t = 0 are known, for one
IV bolus.
2.1.2 Multiple IV Boluses
After a single dose, the plasma drug concentration immediately rises and declines as it is
being eliminated from the body via a first-order process. For an effective treatment, Cp
should be maintained between a minimum effective concentration (MEC) and a
minimum toxic concentration (MTC) for the duration of therapy. Because such a profile
is not possible with one intake, multiple-dosing regime is often prescribed. Subsequent
doses taken at appropriate time intervals lead to the accumulation of medicament in the
body and therefore, help to keep a desired range.
The concentration at the end of the first dosing interval is obtained from Equation
2.2:
where the 't refers to the time since the last dose and the subscript "1" is the number of
doses (i.e. in this case, one dose).
This gives the plasma concentrations at the end of first interval, where t is the
dosing interval in seconds or minutes or hours.
At the beginning of the second interval, the concentration becomes,
At the end of the second dose interval, the concentration becomes
This calculation results in a geometric series with each term e -kel*t times the
preceding term. Hence, for n doses, the concentration introduced will be
And the concentration at any time t after n doses i.e., Cp Immediately after the nth
dose is given by
After further manipulations, the equations can be written as:
6
and
respectively.
7Equations are derived for maximum (Cpmax) and , minimum (Cpmin) concentrations
that can be achieved after an infinite number of boluses:
and
2.1.3 Infusion
Drugs are administered intravenously in the form of a bolus dose or infused relatively
slowly through a vein into the plasma at a constant or zero-order rate. One of the main
advantages of an IV infusion is that an effective constant plasma drug concentration can
be achieved, thereby eliminating the fluctuations observed in bolus IV dosing.
An infusion rate term is added to the mass balance of one-compartment model, to
give:
In this formulation, k0  is the input and V * kel * Cp
 is the output.
The integration of Equation (2.13) gives:
where,
k0 = infusion rate (Zero order) (g/hr)
kel = elimination rate constant (First order) (min -1)
Cp
 = concentration in Plasma (g/L)
8V = distribution volume (mL) 200 mL
t = time (minute)
2.1.4 IV Boluses and Infusion
An initial bolus is given prior to infusion to reach the desired concentration as quickly as
possible. The concentration of the drug in body after an IV bolus is described as:
with initial condition of Cp(0) = Co.
The integration of Equation (2.15) gives:
2.1.5 Experiments with one-compartment Model
There were various experiments performed using one-compartment model. The
experiments were performed for single and multiple IV boluses, infusion with and
without IV boluses. The effect of the model parameters on Cp was also studied. The
materials and the experimental setup are given below:
9Materials and Experimental Setup
• Variable flow-rate pump 2 (Clearance and water supply pump)
• 250-mL or 200-mL Beaker 1 (Central compartment)
• 4-L Beaker 2 (Water reservoir and waste beaker)
• Stopwatch 1 (Time measurement)
• 10-mL Graduate cylinder 1 (Flow rate calibration)
• Pipette 1 (Bolus drug administration)
• Rubber tubes (Fluid transport)
• Magnetic stirrer 1 (Liquid mixing in central compartment)
• Magnetic bar 1 (Liquid mixing in central compartment)
• Potassium permanganate (Drug)
• Spectrophotometer (Absorbance/concentration measurement)
• Cuvette 4 (Sample in spectrophotometer)
• Laboratory stand 1 (Rubber tubes mounting)
• Clamp 4 (Rubber tubes mounting)
• Transfer pipette 1 (Drug administration)
The apparatus is shown in the Figure 2.3. The beaker with the KMnO 4 solution
was placed on a magnetic stirrer. A pump was used to mimic drug clearance from the
body (i.e., waste pump). Water was introduced with the same rate as the pump used to
mimic drug clearance, in order to maintain a constant volume of liquid in the central
compartment. The rubber tubes are fastened firmly with clamps.
10
Figure 2.3 Experimental setup of one-compartment model.
Method of Measuring Concentration
A spectrophotometer is used to measure the concentration of KMnO 4 in the solution. A
calibration curve was developed to relate the concentration with the absorbance reading
at a wavelength of 530 nm. The solution prepared for this purpose is 2 g KMnO 4 in
1000m1 water (i.e., concentration is 0.002 g/ml). The data are shown in Table 2.1.
11
Table 2.1 Calibration Table for Concentration versus Absorbance
Absorbance (A) Concentration (g/ml)
0.126 0.002
0.063 0.001
0.032 0.0005
0.016 0.00025
The relationship that results from the above table is C = 0.016*A, where C is
concentration in g/ml and A is the absorbance. Hence, the relationship between the
concentration of the drug and the absorbance is established. This relationship is used to
then record the concentration of the drug during the experiments with one-compartment
model.
2.2 Two-compartment Model
A two-compartment model is used to represent the drug absorption, distribution and
elimination in the body. This representation addresses cases in which the concentration
profiles are different in the blood and surrounding tissue.
12
Figure 2.4 Representation of two-compartment model.
2.2.1 IV Bolus
In a two-compartment framework, one vessel, representing the blood and the
extracellular fluid is the central compartment. The highly perfused tissues are represented
by the other vessel, which is the peripheral compartment. The drug distributes rapidly and
uniformly in the central compartment whereas the distribution is slower in the peripheral
compartment.
Figure 2.5 Representation of the experimental setup for two-compartment model.
Mass balances over the system in Figure 2.5 give,
and
The mass balance equations are derived and shown in the Appendix A,
with the initial conditions:
13
and
Applying the Laplace transform as discussed in Appendix B,
to Equations.(2.17) and (2.18), we obtain
and
From the above equation we have,
Substitution of Equation (2.21) into Equation (2.19) yields
and
14
Equation (2.22) can be rearranged to give
Equation (2.24) can be written as
15
and
where a and b are both given by:
Here, both a and b are distinct and real because
The inverse Laplace transform of Equations (2.25) and (2.26) are
and
2.2.2 Multiple IV Boluses
Multiple-dosing regime is often prescribed to maintain the plasma drug concentration
between a minimum effective concentration (MEC) and a minimum toxic concentration
(MTC) for the duration of the therapy. Equations (2.17) and (2.18) give the mass balance
over the system defined in Figure 2.5. The initial conditions for this case are:
and
Applying the Laplace transform to Equations (2.17) and (2.18) we obtain
and
Equation (2.29) can be written as
16
The inverse Lanlace transform of Eauations (2.31) and (2.30) give
and
17
Here, both a and b are distinct and real as discussed in the case of IV Bolus.
2.2.3 Infusion
Many drugs are administered by IV infusion. This requires the drug, to distribute itself in
the tissue and reach equilibrium with the plasma drug concentration.
Equations (2.17) and (2.18) represent component balance over the system defined
in Figure 2.5. An input term is added, in this case. Let R be that infusion rate term in
(g/hr).
and
with the same initial conditions as in multiple IV boluses.
Applying the Laplace transform to Equations (2.35) and (2.36) we obtain,
and
From the above Equation (2.38) we have,
Substitution of Equation (2.39) into (2.37) yields
and
Here, R' = R/V1 and also the above equation can be written as
and
18
The inverse Laplace of the above equations gives
19
Here, both a and b are distinct and real as discussed in the case of IV Bolus.
2.2.4 IV Boluses and Infusion
It is always desirable to achieve a rapid therapeutic drug level in plasma by using a
loading dose. The drug distributes slowly into extravascular tissues and hence the drug
equilibrium is not immediate.
The mass balance is the same as in the infusion case but the initial conditions are,
and
Applying the Laplace transform to Equations (2.35) and (2.36), we obtain
and
From the above Equation (2.47) we have:
Substitution of Equation (2.48) into (2.47) yields
The above equation can now be written as
The inverse Laplace of the above equation gives
2.2.6 Experiments with two-compartment Model
There were various experiments performed using one-compartment model. The
experiments were performed for single and multiple IV Boluses, infusion with and
without IV boluses. The effect of the model parameter on Cp was also studied. The
materials and the experimental setup are given below:
Materials and Experimental Setup
• Variable flow-rate pump 5 (Clearance and water supply pump)
• 250-mL or 200-mL Beaker 2 (Central and Peripheral compartment)
• 4-L Beaker 2 (Water reservoir and waste beaker)
• Stopwatch 1 (Time measurement)
• 10-mL Graduate cylinder 1 (Flow rate calibration)
• Pipette 2 (Bolus drug administration)
20
21
• Rubber tubes (Fluid transport)
• Magnetic stirrer 2 (Liquid mixing in central compartment)
• Magnetic bar 2 (Liquid mixing in central compartment)
• Potassium permanganate (Drug)
• Spectrophotometer (Absorbance/concentration measurement)
• Cuvette 8 (Sample in spectrophotometer)
• Laboratory stand 2 (Rubber tubes mounting)
• Clamp 4 (Rubber tubes mounting)
• Transfer pipette 1 (Drug administration)
The apparatus is shown in the Figure 2.6. The beakers with the water were placed
on a magnetic stirrer. A pump was used to mimic drug clearance from the body (i.e.,
waste pump). Water was introduced with different rates into both the vessels, in order to
maintain a constant volume of liquid in the central compartment. Two more pumps were
used to transfer fluid from the central to the peripheral compartment and vice versa. The
rubber tubes are fastened firmly with clamps.
22
Figure 2.6 Experimental setup of two-compartment model.
Method of Measuring Concentration
The procedure is similar to the one used in the case of one-compartment model. The same
calibration line is used.
CHAPTER 3
EXPERIMENTAL SECTION
3.1 Experiments on One Compartment Model
3.1.1 Single IV Bolus
An intravenous injection (IV bolus) ensures that a certain amount of drug is made
available in the circulation instantaneously by avoiding the first pass effect. Also, the
time taken to administer the drug is comparatively less [4, 5]. An IV bolus of 0.04 g is
administered to the vessel.
Assumptions-
1. The distribution of the drug is instantaneous and homogenous throughout the
compartment.
2. The drug introduced in the blood stream comes to a rapid equilibrium with the
drug in the extra vascular tissues.
3. There is also rapid mixing; the drug mixes instantaneously with the blood. The
mixing time is small when compared to the sampling time.
4. The rate of change of drug concentration is directly proportional to the drug
concentration in the compartment.
Experimental Procedure-
The flow rates were adjusted until a target volume V was acheived in the central
compartment. These flow rates were calibrated prior to performing the experiments using
a stopwatch and a graduated cylinder. At the beginning of each experiment, l.5-mL of
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sample was taken from the beaker to the spectrophotometer (set at 530 nm) and served as
a blank. The first data point was collected and its absorbance measured right after a
prescribed loading dose was injected into the compartment using a transfer pipette.
Similar measurements were recorded at regular time interval after 10ml of tracer was
added to the central compartment. Dilutions were necessary, in some case's, to keep the
absorbance readings within the range covered by a calibration line: y = 0.0016 x A
where y represented the concentration in g/mL and A the absorbance.
3.1.2 Multiple IV Boluses
After a single-dose administration, the plasma drug level immediately rises above a
minimum effective concentration. However, if a second dose is not taken at a specific
time, the drug may not be useful as the plasma concentration drops well below the
therapeutic level. Such a situation can be circumvented by prescribing a multiple-dosing
regimen to the patient [7].
Multiple boluses of 0.04 g are administered to the vessel at very 60 seconds. The
elimination rate constant is 0.028 second-1 . In this case, the loading dose equals the
maintenance dose.
Assumptions-
The assumptions made in IV bolus still hold. In addition, the principle of superposition
assumes that early doses of drug do not affect the pharmacokinetics of the subsequent
doses.
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Experimental Procedure-
A procedure, similar to the one adopted in the case of a single IV bolus, was used. Nine
IV boluses of 0.04 g are added at an interval of 60 seconds each, the samples are
collected every 15 seconds.
3.1.3 Effect of Size of Dose and Dosage Interval
There are two main parameters that can be manipulated in developing a dosage regime:
(1) The size of the drug dose (dosage size) and
(2) The frequency of drug administration (i.e., the time interval between doses or the
dosage interval).
Studies were conducted to assess, how initial doses and drug-dosing intervals affected
drug concentration in the central compartment.
In the first part of the experiment, the loading dose was 0.073 g which was later
changed to 0.11 g, for 9 IV boluses. In the second part, dosing interval was changed from
45 to 30 seconds for loading doses of 0.073 g and 0.11 g. The loading dose equals the
maintenance dose in all the above cases. The elimination rate constant is 0.028 second-1
in all the above-mentioned cases.
Assumptions-
The assumptions made in the case of multiple IV boluses also apply in this study.
Experimental P ro cedure-
The method outlined in the case of a single IV bolus, was used.  In addition, 9 IV boluses
are added at an interval of 45 seconds each whereas the samples are collected every 15
seconds. This procedure is followed when studying the effects of the dosage size and
administration time.
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3.1.4 Effect of Time Dependent Kinetics
The elimination rate directly effects the distribution of the drug in one compartment
model. In some cases depending on the duration, this may accurately explain long term
clinical studies. Changes in elimination rate were reported in [9].
The loading dose is 0.17 g and elimination rate constant is 0.014 min 1 , which is
changed at frequent intervals.
Assumptions-
In addition to the assumptions made in the previous case, the elimination rate constant
changes instantaneously, with the outlet flow rate.
Experimental Procedure-
The method outlined in the case of an IV bolus, was used. In this case, a new dose is
added every 45 minutes and samples are collected at an interval of 15 minutes. During
the addition of a new dose, the inlet and outlet flow rates of water are changed
simultaneously to maintain the liquid level in the beaker.
3.1.5 Infusion
The main advantage for administering a drug by IV infusion is that IV infusion allows
precise control of plasma drug concentrations to fit the individual needs of the patient.
For drugs with a narrow therapeutic window, IV infusion maintains an effective constant
plasma drug concentration by eliminating wide fluctuations. Furthermore, the duration of
drug therapy may be maintained or terminated as needed using IV infusion. To reach a
MEC, a bolus dose requires some time to be completely diluted in blood and hence, slow
infusion is preferred [5].
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Assumptions-
The assumptions made in the multiple IV cases still hold.
Experimental Procedure-
The method outlined in the case of a multiple IV boluses, was used. However, in this case
the infusion was started at t = 0 and samples were collected at an interval of 15 minutes.
3.1.6 IV Bolus and Infusion
The time taken by the drug to reach a steady-state value is very long with IV Infusion. To
circumvent this problem, multiple boluses are often used prior to initiate a constant-rate
infusion. This experiment is conducted in two parts:
(a) One compartment model with infusion and one IV bolus
(b) One compartment model with infusion and multiple IV boluses.
The experiment was carried out to achieve a steady-state value of 0.36 g in the
compartment with kel = 0.014 min-1 and ko = 5.6 g/min.
Assumptions-
The assumptions made in the multiple IV cases were applied.
Experimental Procedure-
For part (a) at time t = 0 the flow of drug into the compartment began at the same time an
bolus of 0.4 g was added, whereas for part (b) of the experiment, two cases were used:
two IV boluses in one case and four IV boluses in another case, both  combined with an
infusion. A loading dose, (equivalent to the maintenance dose) of 0.4 g was used. The
aim of the study was to find out which of the two cases showed the best performance.
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3.2 Experiments on Two Compartment Model
3.2.1 Single IV Bolus
A two-compartment model gives a good representation of the human body, where the
central compartment represents the blood and the peripheral compartment represents the
tissues [11] .
An IV bolus of l.37 g is administered to the central compartment.
Assumptions-
The assumptions made in the previous cases still apply.
Experimental Procedure-
The method outlined in the case of a single IV bolus, was used.
3.2.2 Multiple IV Boluses
The administration of a single bolus will cause the plasma drug concentration to fall
below the MEC. To avoid such a situation, a second bolus has to be administered [4].In
order to develop a drug administration regime with multiple boluses for a two-
compartment model. The kinetic rate constants should be known. These kinetic rate
constants define the transport between both compartments [14].
A drug administration regime has been developed with three IV boluses having a
loading dose of 0.82 g. The first and last maintenance doses are 0.314 g and 0.242 g
respectively. The kinetic rate constants are the same as in those used in the previous
experiment: k12 =1.7999 hr -1 , k21 = 2.9246 hr -1
 and kel= 0.2739 hr-1
Assumptions-
The assumptions made in the previous cases still apply.
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Experimental Procedure-
The method outlined in the case of a single IV bolus in a two-compartment model was
used. The samples were collected at an interval of 15 minutes for both the central and the
peripheral compartments. The first and the second maintenance dose were added to the
central compartment at 90 minutes and 180 minutes, respectively.
3.2.3 Effect of Time Dependent Kinetics
The kinetic rate constants play a very important role in determining the elimination of the
drug from the central compartment as well as the transport of the drug between the two
compartments. A change in any of these constants effects the drug distribution.
There are three rate constants, k12, k21 and kei, which are identified in the setup.
The kinetic rate constant k12 is responsible for the transport of drug from the central to the
peripheral compartment, whereas the kinetic rate constant k 21 is responsible for the
transport of drug from the peripheral to the central compartment. The kinetic rate
constant kei is responsible for the elimination of the drug from the central compartment.
Changes are made to one rate constant, keeping the other two constant. The effects of the
time dependent kinetics are studied.
Assumptions-
The assumptions made in the previous case were applied. In addition, it is assumed that
the elimination rate constant changes instantaneously, with the flow rate of the outletstream.
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Experimental Procedure-
The method outlined in single IV bolus in two-compartment model, was used. The flow
rates governing the kinetic rate constants are changed, prior to adding the KMnO4
solution.
3.2.4 Infusion
The main advantage for giving a drug by IV infusion is that this method allows precise
control of the plasma drug concentrations. The drug is infused in the central compartment
where it is eliminated and also transported into the peripheral compartment. The desired
effect is observed in the central compartment [16].
A drug administration regime has been developed to maintain 0.695 g of drug in
the central compartment. The kinetic rate constants used in the experiment are k 12 =
1.0968 hr-1, k
21
 = 2.3596 hr-1
 and kel= 1.4335 hr-1
Assumptions-
The assumptions made in the previous case still hold.
Experimental Procedure-
The method outlined for a single IV Bolus in two-compartment model was used. The
samples were collected at an interval of 15 minutes for both the central and the peripheral
compartment. The infusion is started at time t = 0.
3.2.5 IV Boluses with Infusion
Drug administration by IV infusion is very effective since there is precise control over the
plasma drug concentration. It is also possible to maintain the drug concentration within a
specific range.  The time taken by the drug to reach the effective level is generally very
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high during infusion. This time could be reduced by administering IV boluses as
suggested in [18].
A drug dosage regime was developed with a loading dose of 0.808 g and two
maintenance doses of 0.201 g and 0.196 g coupled with infusion rate of 0.996 g/hr, where
the infusion is started at t = 0.5 hr.
Assumptions-
The assumptions made in the previous case still hold.
Experimental Procedure-
The method outlined in the case of multiple IV Boluses is used. A loading dose of 0.808
g is given at time t = 0 and two maintenance doses of 0.201 g and 0.196 g were
respectively given at time t = 0.12 hour and t = 0.254 hour .The infusion is started at time
t = 0.5 hours.
CHAPTER 4
RESULTS AND DISCUSSIONS
4.1 Experiments on One Compartment Model
4.1.1 Single IV Bolus
A sample is taken every 30 seconds. The concentration profile is exponentially
decreasing which can be seen from Figure 4.1. It can also be concluded that if multiple
boluses were to be injected, the next bolus should be between 40 and 60 seconds after the
first bolus has been administered for the same loading dose. The data analysis as
discussed in Appendix C.l which yields an elimination rate of 0.028 second -1 . This value
of the elimination rate is used for future experiments with one compartment model.
The sum of the squared difference between the experimental and the calculated
profile is very small. The concentration profile obtained for the drug is very similar to the
concentration profile obtained for Nafcillin in [6] is as shown in Figure 4.2.
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Figure 4.1 Plasma drug concentration-time profile for a single bolus dose. Loading dose
is 0.04 g, kel = 0.028 second-1 . The symbols (♦) represent the experimental profile and (■)
represent the calculated profile.
Figure 4.2 Plasma concentration profile due to one IV bolus (Nafcillin) : C 0p =29.
1 ug/mL, kel = 0.483 hr-1.
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4.1.2 Multiple IV Boluses
During repeated drug administration, the concentration profile will be repeated for each
dosage interval [8]. 9 IV boluses are given in the experiment. The experimental data is
shown below in Figure 4.3, whereas the calculated data are shown in Figure 4.4. The
concentration profile obtained experimentally is very similar to the concentration profile
for Naficillin in [6] as shown in Figure 4.5.
Figure 4.3 Plasma drug concentration time profile for a one compartment model with
nine IV Boluses. Loading dose is 0.04 g, kel = 0.028 second-1, n = 9 and τ = 60 second.
The symbols (♦) represent the experimental profile.
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Figure 4.4 Theoretically calculated plasma drug concentration time profile for one
compartment model with nine IV Boluses. Loading dose is 0.042 g, kel
 = 0.028 second-1,
n = 9 and τ = 60 sec. The symbols (■) represent the calculated profile.
Figure 4.5 Plasma concentration profile for a multiple IV bolus regimen. The parameters
for nafcillin, C0p = 29.1 μg/mL and kel = 0.483 hr-1 . For the simulation, n = 10 and τ = t 1/2
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The Cpmax and the Cpmin values reached during the experiment are respectively
0.24645 g/L and 0.0477 g/L, whereas theoretical C
pmax
 and the Cpmin values obtained are
respectively 0.24623 g/L and 0.04589 g/L. The sum of the squared difference between
the calculated profile and the profile obtained experimentally is 0.0007.
4.1.3 Effect of Size of Dose and Dosage Interval
Part 1 of the experimental results obtained is shown in Figure 4.6. Each drug has a toxic
level and a non effective level in the human body. When the drug is administered into the
human body, it should not exceed the MTC so as not to become harmful and should not
fall below MEC. As a result, Cpmax and the Cpmin
 
are within MTC and MEC. Using this
information, coupled with the desired maximum and minimum concentration, the dose
interval can be decided. The values obtained experimentally are very close to the
theoretical values.
These findings suggest that the two doses leads to a different maximum and
minimum. The number of doses required to reach a steady cycle is the same because
there is no change in the dose interval.
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Figure 4.6 Plasma drug concentration time profile for one compartment model with nine
IV Boluses with two drug sizes. Here, Dose # 1 is 0.073 g represented by (● ) and Dose #
2 is 0.109 g represented by (■), kel = 0.028 second-1 for both and τ = 45 seconds.
For the second part of the experiment, the dosage interval is changed from 45
seconds to 30 seconds. The results are shown in Figure 4.7 and Figure 4.8. Since the
dosage interval is changed for both loading dose's, it can be seen that a new higher
maximum and minimum values are obtained at τ = 30 seconds which are higher than the
values obtained when τ = 45 seconds. The change in dosage interval has a profound
impact on the distribution regime. If the dosage interval is shortened, higher maximum
and minimum levels will be obtained. The profile observed during multiple IV boluses
mimic a infusion for very short administration time.
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Figure 4.7 Plasma drug concentration time profile for the change in dose interval. Dose #
1 = 0.073 g, kel = 0.028 second-1 for τ = 45 sec (●) and τ = 30 sec (■).
Figure 4.8 Plasma drug concentration time profile for the change in dose interval. Dose #
2 = 0.109 g, kel = 0.028 second -1 for τ = 45 sec (● ) and τ = 30 sec (■).
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4.1.4 Effect of Time Dependent Kinetics
The change in the elimination rate is shown graphically in Figure 4.9 and the
concentration profile of the drug when the elimination rate is changed during the addition
of a new dose is shown in Figure 4.10.
Figure 4.9 Change of the rate constant of elimination during the length of the
experiment.
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Figure 4.10 The comparison between the plasma drug concentration time profiles with a
constant kel = 0.014 minute -1(●) and a plasma drug concentration time profile with
varying Ice (■). Loading dose = 0.169 g and τ = 45 min.
Figure 4.10 provides a comparison between the 1 st case where the elimination
constant remains at 0.014 min -1 and the 2nd case where the kel changes during the
experiment. The concentration profiles are similar for both cases as the k el values are the
same.
Before the second dose is administered the kel value has been changed to 0.028
min-1 which is higher than that of the first dose, so the maximum concentration reached
by both cases are the same but the minimum concentration reached is lower.
The third dose in both the cases, have the same kel value but the maximum values
attained are different, as the minimum value attained for the 2nddose is lower and hence
when the third dose is added the maximum reached is lower than that achieved in the 1 st
case.
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The fourth dose is introduced at a very low kel (  = 0.006 min-1) value in the 2nd
case. The maximum values reached at 135 minutes are also the same for both the cases.
However, more accumulation is observed in the 2nd case due to the lowel  value. As a
result, the concentration of KMnO4 is higher in the 2nd case than the 1 st case when t = 150
min.
The fifth dose is introduced at a higher el ( el = 0.021 min-1) value in the 2 nd case.
As the fourth dose was at a very low el value the minimum reached is very high
compared to that of the fourth dose in the 1 st case, so the maximum value for the fifth
dose is higher in the 2nd case. Also, the minimum reached is lower for the fifth dose in the
2nd case when compared to the fifth dose in the l st case.
The el values are the same for the sixth dose. Since the minimum reached for the
fifth case in the 2nd case was lower than that of the 1 st, the maximum reached for the sixth
dose is higher for the 1 st case. As the value of el for the 2nd case decreased from 0.021
min-1 to 0.014 min-1 there is accumulation of KMnO 4 which is shown by the sample at
240 minutes. The minimum achieved for both cases are similar. Similar trends are
observed for the remaining doses.
Change in el can severely affect the concentration profile of the drug in the body.
The increase in el values leads to the faster remova  of drug from the system; the drug
may then drop below the effective level. The decrease inel  values leads to the slower
removal of drug from the system; the drug may accumulate in such amounts as to cross
the toxic level and become harmful for the body.
If the el value changes in the course of treatment, the drug may reach a value that
is harmful to the patient. The development of drug regimen in accordance with changing
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kel
 
is very difficult as there is no method to determine how kel will change and
correspondingly how it will affect the plasma drug concentration.
4.1.5 Infusion
During constant-rate infusion, the concentration increases exponentially. When the
infusion is stopped, the amount of drug decreases [10]. Experimental and predicted time
concentration profiles are shown in Figures 4.11 and 4.12, respectively. A similar trend is
observed for the constant rate infusion of Ampicillin Trihydrate in [5]. The sum of the
squared difference between the calculated profile and the experimentally obtained profile
is 0.004329. The time it takes to reach the steady state value of 0.4 g is 165 minutes.
Figure 4.11 The symbols (♦) represent the experimental concentration profile for kel =
0.014 min-1 and ko = 5.6 g/min.
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Figure 4.12 Calculated concentration profile is represented by the symbols (■) for
k
l  =
0.014 mid i and ko = 5.6 g/min.
4.1.6 IV Boluses and Infusion
The concentration profile for one IV bolus with Infusion is shown in Figure 4.13, the
results for four and two IV boluses with Infusion are shown in Figure 4.14.
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Figure 4.13 Plasma concentrations versus time for one IV bolus with infusion are
represented by (■), with loading dose of 0.4 g, kel
 = 0.014 min -1 and ko
 = 5.6 g/min.
Figure 4.14 Plasma concentrations versus time for two (●) and four IV boluses (■) with
loading dose as 0.4 g and 
k
el = 0.014 min-1 followed by a constant-rate infusion of
0  = 5.6 g/min.
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Part (a)
From Figure 4.13, it can be concluded that one IV bolus is not sufficient for the
compartment to achieve a steady state value of 2 g/L quickly through the infusion. To
lessen the time it takes to reach the steady state value, two boluses with infusion and four
boluses with infusion are tested. The sum of the squared difference between the
calculated profile and the profile obtained experimentally is 0.8332.
Part (b)
In the experiment of four IV Boluses with IV Infusion the concentration of the drug
reaches a very high value. It is possible for the system to reach steady state value with
lower number of IV boluses as the minimum concentration reached after two boluses is
nearer to the steady state value of 2 g/L. Experiment with two IV boluses with Infusion is
was conducted. A response time of 120 minutes was recorded. The sum, of the squared
difference between the calculated profile and the profile obtained experimentally for two
IV boluses with infusion is 0.1179, and for four IV boluses with infusion is 0.1322.
4.2 Experiments using Two Compartment Model
4.2.1 Single IV Bolus
The experimental and calculated concentration profiles for two compartment model are
shown in Figure 4.15 Figure 4.16, respectively.
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Figure 4.15 Concentration profile for two-compartment model with initial dose 1.37 g.
The symbols (▲ ) and (■) represent the profile for the central and peripheral
compartment, respectively.
Figure 4.16 Calculated concentration profile for two compartment model, with a initial
dose of 1.37 g. The symbols ( ♦ ) and (■) represent the profile for the central and
peripheral compartment respectively.
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The sum of the squared difference between the calculated profile and the profile obtained
experimentally is 0.17 for the central compartment and 0.000545 for the peripheral
compartment. The data was analyzed using a method similar to that adopted in [12].
Details are provided in Appendix C.2. The estimated values of the kinetic rate constants
obtained after data analysis are k 12 = l.7999 hr-1 , k21 = 2.9246 hr-1 and kel= 0.2739 hr-1
The concentration profile in the central compartment is similar to the one described in
[13].
4.2.2 Multiple IV Boluses
Experimental and predicted concentration profiles are shown in Figures 4.17 and 4.18,
respectively. The predicted values obtained using the code is outlined in Appendix D.l.
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Figure 4.17 Concentration profile for multiple boluses, with a loading dose of 0.82 g.
The first and second maintenance doses are 0.314 g and 0.252 g, respectively. The kinetic
rate constants are k 12 = 1.7999 hr-1, k21 = 2.9246-1  and kel= 0.2739 . The symbols
(♦ ) and (■ ) represent the profile for the central and peripheral compartment respectively.
The sum of the squared difference between the calculated profile and the profile
obtained experimentally is 0.14 for the central compartment and 0.217 for the peripheral
compartment. The dosage regime developed is very close to that obtained experimentally.
A similar trend for multiple boluses is observed in [15].
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Figure 4.18 Calculated concentration profile for multiple boluses, with loading dose of
0.82 g. The first and second maintenance doses are 0.314 g and 0.252 g, respectively. The
kinetic rate constants are k 12 = 1.7999 hr-1, k21 = 2.9246 hr-1 and kel = 0.2739 hr-1 .
4.2.3 Effect of Time Dependent Kinetics
The experiment has been conducted in three parts, (1) changing k 12 from l.7993 hr -1 to
1.4023 hr4 while keeping k
21
 and kel constant, (2) changing k  from 2.9246 hr-1 to
3.7948 hr-1 while keeping k
 and kelconstant and (3) changing kfrom 0.2739 hr-1to
0.4129 hr-1 while keeping k
 and k  constant.
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Figure 4.19 Concentration profile for one IV bolus of 1.37 g, where the symbols ( ♦ ) and
(▲ ) represent the profile for the central and peripheral compartment respectively. The
kinetic rate constants are k12 = 1.7993 hr-1 , k21 = 2.9246 hr-1 and kel= 0.2739 hr-1. Where
as the symbols (■) and (X) represent the profile for central and peripheral compartment,
respectively. The kinetic rate constants are k
12
 = 1.4023 hr -1, k
21
 = 2.9954 hr -1 and k el=
0.2815 hr-1 . The standard deviation for kinetic rate constants kl2,k21 and kel are 0.291,
0.617 and 0.098, respectively.
In (l), k was reduced from 1.7993 hr -1 to l.4023 hr -1 . The transport of drug
from the central to the peripheral compartment is decreased. Hence, there is more
accumulation in the central compartment and also the amount of drug in the peripheral
compartment has decreased when compared to the original profile as there is lesser
amount of drug being transported from the central compartment (Figure 4.19).
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Figure 4.20 Concentration profile for one IV bolus of 1.37 g, the symbols ( ♦ ) and (▲ )
represent the profile for the central and peripheral compartment respectively. The kinetic
rate constants as k 12 = 1.7993 hr-1, k21  = 2.9246 hr-1 and kel = 0.2739 hr-1. Whereas the
symbols (■) and (X) represent the profile for central and peripheral compartment
respectively. The kinetic rate constants as k  = 1.6915 hr-1 , k  = 3.7948 hr -1 and kel=
0.2794 hr-1 .
In (2), k  was increased from 2.9246 hr -1 to 3.7948 hr-1 . The transport of drug
from the peripheral to the central compartment is increased. Hence there is more
accumulation in the central compartment. The amount of drug in the peripheral
compartment decreased when compared to the original profile as the amount of drug
being transported to the central compartment increased (Figure 4.20).
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Figure 4.21 Concentration profile for one IV bolus of 1.37 g, the symbols (♦ ) and (▲ )
represent the profile for the central and peripheral compartment respectively. The kinetic
rate constants as k 12 = 1.7993 hr-1 , k21  = 2.9246 hr-1 and kel= 0.2739 hr-1. Whereas the
symbols (■ ) and (X) represent the profile for central and peripheral compartment
respectively. The kinetic rate constants as k  = 1.6566 hr-1 , k  = 3.0903 hr-1 and k el=
0.4129 hr-1 .
In (3), kelwas increased from 0.2739 hr-1to 0.4129 hr. More drug was being
eliminated for the central compartment. A decrease in the accumulation of the drug in the
central compartment was observed. The amount of drug in the peripheral compartment
decreased when compared to the original profile as the amount of drug being transported
from the central compartment has decreased (Figure 4.21).
4.2.4 Infusion
53
Figure 4.22 Concentration profile for IV infusion of 0.695 g of drug having an infusion
rate R = 0.996 g/hr. The kinetic rate constants are k 12 = 1.0968 hr-1, k21  = 2.3596 hr-1 and
kel= 1.4335 hr-1. Here, the symbols (♦) represent the experimental profile and (■
represents the calculated profile.
The drug administration regime was developed to maintain a concentration of 3.46 g/L in
the central compartment. The equilibrium should be reached after 6.75 hours. The
experiment was conducted for 2.5 hours and it is found that the experimental plasma
concentration profile closely follows the designed plasma concentration profile. The sum
of the squared difference between the calculated profile and the profile obtained
experimentally is about 0.0266. Figure 4.22 shows both the experimental and the
calculated concentration profile.
The introduction of IV boluses with IV infusion will reduce the time required to
reach the equilibrium [17].
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4.2.5 IV Boluses with Infusion
The kinetic rate constants used in the experiment are k
12
 = l.0968 hr -1 , k
21
 = 2.3596 hr-1
and kel = l.4335 hr -1 . Refer to Appendix D.2 for the code used to calculate the dosage
regime.
Figure 4.23 Concentration profile for three IV boluses with infusion of 0.695 g of drug
with a loading dose of 0.82 g. The first and second maintenance doses are 0.201 g and
0.196 g respectively. The infusion rate was R = 0.996 g/hr. The kinetic rate constants are
k  = 1.0968 hr-1 , k  = 2.3596 hr-1 and kel= 1.4335 hr-1. The symbols (♦) and (■
represent the profile for the central and peripheral compartment respectively.
The drug administration regime developed to maintain 0.695 g of drug in the
central compartment reaches equilibrium at 6.75 hours with IV infusion which is a very
long time. The equilibrium is reached in 3.5 hours, when three IV boluses with infusion
are administered. Thus, this is a better means of drug administration as compared to
infusion if the plasma concentrations need to reach equilibrium as quickly as possible.
CHAPTER 5
CONCLUSION
The goal of the activities described herein was, to develop drug administration protocols
based on well-stirred vessel experiments. The projects were setup in such a fashion as to
mimic one- and two-compartment pharmacokinetic models. A one-compartment model
assumes that the body is a single chamber. When an API is introduced into the body, the
drug will be evenly distributed throughout the body. The experiments were conducted for
IV bolus, multiple IV boluses, infusion and combined IV boluses with infusion. The
kinetic parameters were calculated by using IV bolus data. These parameters were then
used to design drug administration strategies for the investigated drug regimens. The
results obtained from the experiments are in good agreement to those obtained from
mathematical modeling.
The body can be broadly said to be divided into blood and tissues. This
compartmentalization of the body then leads to the necessity of studying the distribution
of the API between two regions or compartments. A two-compartment model assumes
that the drug is distributed between the blood and tissue, and that the drug concentrations
in both chambers, exhibit distinct transient behaviors. Stirred-vessels experiments were
conducted to represent two-compartment models. The volume of each vessel was
maintained at 200 mL in both the vessels. Administration protocols, similar to the ones in
one-compartment model were used. Predicted and Experimental data were in good
agreement.
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5.1 Future Work
This study focuses on one- and two- compartment representation of the human body. The
addition of more vessels may be more representative of physiologically-based
pharmacokinetic (PBPK) models. The experiments performed used KMnO4. The
introduction of actual drug in the vessels should be studied. Experiments that incorporate
absorption, metabolism and dissolution, would provide additional information to
clinicians.
APPENDIX A
MASS BALANCE EQUATIONS FOR EXPERIMENTAL SETUP OF TWO
COMPARTMENT MODEL
The mass balance equations are derived form the experimental setup shown in Figure 2.6.
The mass balance around the central compartment in Figure 2.5 yeilds,
and the mass balance over peripheral compartment in Figure 2.5 gives,
where ml 1
 and m42 are the rates of mass being added by the water inlet in the central and
peripheral compartments respectively. Also m12, m21 and mei are the rates of mass being
transferred from the central to the peripheral compartment, the mass being transferred
from the peripheral to the central compartment and the mass being eliminated,
respectively. The total mass in the system is not zero.
The change in volume in both the compartments can be obtained by dividing
(A.1) and (A.2) with density.
and
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where
V1 is the volume of the central compartment,
V2 is the volume of the peripheral compartment,
F71 is the volumetric flow rate of water into the central compartment,
F1,2 is the volumetric flow rate of water into the peripheral compartment,
F12 is the volumetric flow rate of water form the central to the peripheral compartment,
F21 is the volumetric flow rate of water form the peripheral to the central compartment,
and Fe is the volumetric flow rate of water being taken out from the central compartment.
As the volume in both the compartment is constant (A.3) and (A.4) become,
and
The mass balance for both the compartment yields
and
Where C1, C2, C41 and C42 respectively stand for the concentration of the drug in the
central compartment, the peripheral compartment, also C1,1 = 0 and C42 = 0. Also the
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volumes in both the compartment are equal. The above equations (A.7) and (A.8)
become,
and
From (A.9) and (A.10), it can be said that
Thus (A.7) and (A.8) can be written as
and
APPENDIX B
LAPLACE TRANSFORM METHOD
This appendix shows on how to solve a differential equation using Laplace Transform.
Assuming that the Laplace transforms of the dependent variable exists, the usual
procedure to solve PDE is
1. Transform the PDE to an ordinary differential equation.
2. Transform the accompanying boundary conditions to those suitable for use with
the ordinary differential equation.
3. Solve the resulting problem using known techniques, in this case variable
separable method.
4. Invert the results to recover the solution to the PDE.
The inversion step can be relatively easy if the terms of step 3 can be located in a
table of Laplace transforms. Without such a convenient table a more difficult technique
involving the residue theorem has to be employed [19].
Iff(x) is a function, letf(x) be defined for 0 < x < ∞ and let s denote an arbitrary
real variable. The Laplace transform of f(x) is then defined as
Now the inverse Laplace transform of F(s) is defined L-1 {F(s)}, is another
function f(x) having the property that L {f (x)} = F(s). The simplest technique for
identifying inverse Laplace transforms is to read them from a table. If F(s) is not in a
recognizable form, it can be transformed into partial fractions.
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An example of using Laplace transform from [20] is shown below:
Taking the Laplace transform of both sides of this differential equation yields
Using known properties of Laplace transforms the above equation becomes:
From which it can be said that
To the linear factors s = 5 and s = 7, the fractions Al(s - 5) and B/(s - 7) can be
associated respectively.
As a result.
Substituting s = 5 and s = 7 we get A = -l/2 and B = 1/2
So,
Taking the inverse Laplace transform of Y(s) gives,
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All of the derivations in the text have been evaluated accordingly.
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APPENDIX C
DATA ANALYSIS
C.1 Data analysis of One-Compartment Model
The data analysis is performed so as to calculated the value of the elimination rate
constant. The concentration profile of a one-compartment model is represented by an
exponential decay which is:
which can further be simplified to,
A plot of ln(C p) vs. t will now produce a straight line, which yields a slope of -a and an
intercept of ln(A).
C.2 Data analysis of Two-Compartment Model
The data analysis is carried out to calculate the kinetic rate constants from the
experiment. The concentration profile obtained is represented by an bi-exponential curve,
which is:
Since the first exponential term decays faster than the second exponential term,
we can conclude that a >> f3.
Hence, for large times:
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which can be written as,
A plot of ln(Cp) vs. t will now produce a straight line for larger times. This straight
line will yield a slope of -β and an intercept of ln(B).
Now since β and B are known, the equation (A.3) transforms into:
and this can be simplified to be written as,
A plot of ln(C p) vs. t will now produce a straight line for smaller times. This
straight line will yield a slope -α and an intercept of ln(A).
Now from the derivation of one IV bolus, as shown in Equation (2.27) we have:
and
Now dividing (A.23) by (A.24) gives,
Hence
It is also know from the derivation of one IV bolus that a and f3 are given by,
here a refers to a and (3 refers to b from the derivation of one IV bolus.
Multiplying a and f3 gives,
now adding a and R gives,
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Hence the values of k12 , k21 and ke, can be calculated.
APPENDIX D
MATHEMATICA CODE
D.1 Mathematica Code for Optimization of Multiple IV boluses
The code shown below is used to optimize a multiple IV bolus regime, for the experiment
performed. Contributed by Dr. Laurent Simon.
ClearAll["Global - *"];
Remove["Global - *"];
Off[General::"spell"]
Off[General::"spell1"]
k1 =0.0141; k2 = 0.01; ke =0.0155;
PENALTY=10;
twidth=0.5;
v1 = 7.811;
v2 = 9.502;
t1s=60;
y1t1s=4.5;
t2s=120;
y1t2s=4.5;
t3s = 200;
y1t3s = 4.5;
tf = 300;
y1inis = 4.5;
y1sets = (0.2) v2;
soll[y1ini_?NumericQ, t1_?NumericQ, t2_?NumericQ,
y1t1_?NumericQ, y1t2_?NumericQ]:=
{y1[t], y2[t]}/.
NDSolve (
{y1: [t] ==- k1 yl It] + k2 y2 [t] - ke yl It] + PENALTY (yltl-yl [t] ) Exp (- ( (t-
t1) /twidth) ^ 2] +PENALTY (y1t2 -y1 [t] )Exp (- ( (t-t2) /twidth)"2] , y2' Et] 1=1 k1 yl Et] - k2 y2 [t] , yl [0] pylini,
y2 [C)] DO .0), {yl, y2}, {t, 0 .0,tf}] [ DJ];
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te_]:=soll[ylini, tl,
t2, yltl, ylt2] [ [1] ] / .t---->te;
y1t1_, y1t2_, te_]:=soll[ylini, t1,
t2, y1t1, y1t2 ] [[2]]/.t->te;
Plot[1/v1 Y1[y1inis, t1s, t2s, y1tls, y1t2s, t1],
{t1,0,tf}, PlotRange-*{0,1}]
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Plot[1/v2 Y2[y1inis, t1s, t2s, y1t1s, y1t2s, t1],
{t1,0,tf}, PlotRange-*{0,0.5}]
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error[y1ini_?NumericQ, t1_?NumericQ, t2_?NumericQ,
_?NumericQ, y1t22NumericQ]:=NIntegrateNy1sets-
sol1[y1ini, tl, t2, y1tl, y1t2][[1]]) 2 , (t,0,tf)]
var ={y1ini, tl, t2, y1tl, y1t2}
fylini,t1,t2,y1t1,y1t21
Table[NMinimize[{error[y1ini, ti, t2, y1tl, y1t2],10 -io-ylini<10, 10 -1°<t2<tf,10 -10<y1tl<10,10 -1°<y1t2<10, t1 <
t2),var,
StepMonitor:>PrintHy1ini,t1,t2,y1t1,y1t2,error[y1ini, tl,
t2,y1t1, y1t2] }] ,MaxIterations-*500] ,{i,1}]//Timing
Plot[Evaluate[1/v1
Y1[3.7216665062542953',75.81998939050332',171.5934461872726
',3.526467545530771',3.416639971477414', t]
	 ], {t,0,tf},
PlotRange-*{0,1}]
Plot[Evaluate[1/v2
Y2 [3. 72 16665062542953',75.81998939050332',171.5934461872726
',3.526467545530771',3.416639971477414', t]
	 ], (t,0,tf),
PlotRange-*(0,0.5)]
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D.2 Mathematica Code for Optimization of IV boluses with Infusion
The code shown below is used to optimize a multiple IV bolus with infusion regime, for
the experiment performed. Contributed by Kwang Seok Kim.
Quit[]
kl=2.73 (*h^-1*) ;k2=3.11 (*h^-1*) ; ke= . 312 (*I -0-
1*);yset=193.9(*mg*);tf=3(*h*);NB=6;
4 k2 ke 1c1 k2 ke_28= 	 ;a=k1+k2+ke+6;13=k1+k2+ke-
6;y=k1-k2+ke-6;6=k1+k2-ke+8;(1)=k1-k2+ke+8;i=k1+k2-ke-6;
yl[0][0]=0;y2[0][0]=0;Table[Ri[j]=0,{j,NB-1}];
Ri[NB]=ke yset;
objfn[tm_,Mb_,NB_]:=Module[fyl,y2,Ri,errl,
Table[Ri[j]=0,{j,NB-1}];
Ri[NB]=ke yset;
yl[0][0]=0;y2[0][0]=0;
y1[j._][t]:=Ri[j]/ke-1/(2 6) (7 (yl[j-
l][tm[[j]]]+Mb[[j]])- 2 k2 y2[j-1][tm[ [j]]]+s Ri[j]/ke)
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[11 	tm_ij 	C 	 +1/(28) (4) (y1[j-1][tm[[j]]]+Mb[[j]])-2 k22 L tni_JJIy2[j-1][tm[ [j]]]+Ri[j] /ke 1)
y2[j ][t ]:=(k1 Ri[j])/(k2 ke)-1/(4k2 5) (I) ( 7 (yl[j-
1][tm[[j]]]+Mb[[j]])- 2 k2 y2[j-1][tm[[j]]]+6 Ri[j]/ke)
Z +1/(4k2 s)_ y 	 (y1[j-1][tm[[j]]]+Mb[[j]])-2
tm_J;111zk2 y2[j-1][tm[[j]]]+Ri[j] /ke i)
err[j_]:=(tm[rj+11]-tm[ [j]]) (Ri[j]/ke-yset) 2+1/(482 a)
(4) (y1(j-1][tm[[j]]]+Mb[ [j]])-2 k2 y2[j-1][tm[[j]]]+Ri[j]
/ke 11) 2 (1-©-(tm[[j+1]]-tm[[j]]) a)+1/(8 a) 2 (4) (y1[j-
1][tm[[j]]]+Mb[[j]])-2 k2 y2[j-1][tm[[j]]]+Ri[j] /ke
2i)(Ri[j]/ke-yset)(1- - ) -2/ (6 13) (7
(yl[j -1 ] [tm[[j]]]+Mb[[j]]) - 2 k2 y2[j-1][tm[[j]]]+6- 1 1_tm_ij  1  E
Ri[j]/ke) (1- — 	 ) (Ri[j]/ke-yset)+1/(4
82 (3) (y (y1[j-1][tm[(j]]]+Mb[[j]])- 2 k2 y2[j-1][tm[[j]]]+E
Ri[j]ike) 2 (14)-(tart[[j+1]]-tra[[j]]) 13) -1/ ( (a+0) 82) (y (y1 [j-
l][tm[[j]]]+Mb[[j]])- 2 k2 y2[j-1][tm[[j]]]+E Ri[j]/ke) ((I)
(yl[j-l][tm[[j]]]+Mb[[j]])-2 k2 y2[j-1][tm[[j]]]+Ri[j] /ke
- 1 1 	 tm 	 1  1111 E_
ii) (1--
	);
obj= Total_Table_err_ij_, 	 NB_ / (tm[ [NB+1] ]
yset)
];
ToExpression[StringJoin[ufabcP,TableWarg",ToString[i],"_
?NumericQ,"},{i,2,2NB-
1}],("arg",ToString[2NB]," ?NumericQ]:=objfn[{0,"},Table[{"
argli,ToString[i],","},{i,27/4B}],ToString[tf],"1,{",Table[{"
arg",ToString[i],","},{i,NB+1,2NB-
1}],{"arg",ToString[2NB],"},",ToString[NB],"]"}]]
opt=ToExpression[StringJoinPNMinimizeHrr=fabcP,TableWa
rg",ToString[i],","1,{i,2,2NB-
71
11],("arg",ToString[2NB]),"],0",Table[("<arg",ToString[i]),
{i,2,NB}],"<tf",Table[{",0<arg",ToString[i]},{i,NB+1,2NB}],
"),(",Table[("(arg",ToString[i],",",ToString[.5tf (i-
1)/NB],",",ToString[1.05*.5tf (i-
1)/NB],"1,"1,0.,2,NBILTable[1"(argyv ToString[i],",",ToStri
ng[(1.1*yset)/(i-NB)],",",ToString[1.1 (1.1*yset)/(i-
NB)],"),"),(i,NB+1,2NB-
1)],("(arg",ToString[2NB],",",ToString[(1.1*yset)/NB],",",T
oString[1.1 (1.1*yset)/NB],"}"}„"),Method-
>NelderMead,StepMonitor:>Print[(",Table[{"arg",ToString[i],
","}„(i,2,2NB}],"rrl]]//Timing"]]
{0. 256844, 0. 524692, 0. 763214, 1. 02454, 1. 27777, 218. 152, 108. 788
,77.0006,54.386,45.6221,35.8972,0.120199}
{0.261794,0.507003,0.739698,1.07134,1.28919,228.126,102.492
,69.5479,53.0547,40.7593,36.285,0.106997}
{0.261794,0.507003,0.739698,1.07134,1.28919,228.126,102.492
,69.5479,53.0547,40.7593,36.285,0.106997}
{0. 261794, 0. 507003, 0. 739698, 1. 07134, 1. 28919, 228. 126, 102. 492
,69.5479,53.0547,40.7593,36.285,0.106997}
{0. 261794, 0. 507003, 0. 739698, 1. 07134, 1. 28919, 228. 126, 102. 492
,69.5479,53.0547,40.7593,36.285,0.106997}
{0.261794,0.507003,0.739698,1.07134,1.28919,228.126,102.492
,69.5479,53.0547,40.7593,36.285,0.106997}
{0.265709,0.524691,0.77833,1.091,1.28374,203.585,103.276,70
.7459,53.709,48.2389,34.1232,0.0981872}
{0.265709,0.524691,0.77833,1.091,1.28374,203.585,103.276,70
.7459,53.709,48.2389,34.1232,0.0981872}
{0.265709,0.524691,0.77833,1.091,1.28374,203.585,103.276,70
.7459,53.709,48.2389,34.1232,0.0981872}
{0.261292,0.524978,0.768091,1.09177,1.31972,205.786,105.723
,63.2749,49.3023,45.6322,35.1527,0.0859107}
{0.261292,0.524978,0.768091,1.09177,1.31972,205.786,105.723
,63.2749,49.3023,45.6322,35.1527,0.0859107}
{0.261292,0.524978,0.768091,1.09177,1.31972,205.786,105.723
,63.2749,49.3023,45.6322,35.1527,0.0859107}
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{0. 260851, 0. 497845, 0. 758532, 1. 13847, 1. 33182, 195. 021, 104. 448
,57.2816,47.8493,43.9384,35.3271,0.0728156}
{0.260851,0.497845,0.758532,1.13847,1.33182,195.021,104.448
,57.2816,47.8493,43.9384,35.3271,0.0728156}
{0. 260851, 0. 497845, 0. 758532, 1. 13847, 1. 33182, 195. 021, 104. 448
,57.2816,47.8493,43.9384,35.3271,0.0728156}
{0.260851,0.497845,0.758532,1.13847,1.33182,195.021,104.448
,57.2816,47.8493,43.9384,35.3271,0.0728156}
{0. 260851, 0. 497845, 0. 758532, 1. 13847, 1. 33182, 195. 021, 104. 448
,57.2816,47.8493,43.9384,35.3271,0.0728156}
{0.260851,0.497845,0.758532,1.13847,1.33182,195.021,104.448
,57.2816,47.8493,43.9384,35.3271,0.0728156}
{0.266224,0.5312,0.778558,1.19951,1.36635,194.246,90.5743,5
1.6953,39.162,47.1681,34.4037,0.0667614}
{0.266224,0.5312,0.778558,1.19951,1.36635,194.246,90.5743,5
1.6953,39.162,47.1681,34.4037,0.0667614}
{0. 262797, 0. 511979, 0. 73595, 1. 15584, 1. 33733, 194. 601, 96. 0628,
53.8296,42.4777,42.0683,33.6936,0.06357}
{0.262797,0.511979,0.73595,1.15584,1.33733,194.601,96.0628,
53.8296,42.4777,42.0683,33.6936,0.06357}
{0.262797,0.511979,0.73595,1.15584,1.33733,194.601,96.0628,
53.8296,42.4777,42.0683,33.6936,0.06357}
{0. 262797, 0. 511979, 0. 73595, 1. 15584, 1. 33733, 194. 601, 96. 0628,
53.8296,42.4777,42.0683,33.6936,0.06357}
{0.262797,0.511979,0.73595,1.15584,1.33733,194.601,96.0628,
53.8296,42.4777,42.0683,33.6936,0.06357}
{0.262797,0.511979,0.73595,1.15584,1.33733,194.601,96.0628,
53.8296,42.4777,42.0683,33.6936,0.06357}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
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39.3218,39.138,35.8432,34.0357,0.05493821
{0. 276033, 0. 499443, 0. 713619, 1. 28151, 1. 3681, 219. 943, 77. 9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0. 276033, 0. 499443, 0. 713619, 1. 28151, 1. 3681, 219. 943, 77. 9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0. 276033, 0. 499443, 0. 713619, 1. 28151, 1. 3681, 219. 943, 77. 9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0.276033,0.499443,0.713619,1.28151,1.3681,219.943,77.9381,
39.3218,39.138,35.8432,34.0357,0.0549382}
{0. 250764, 0. 526959, 0. 75088, 1. 24455, 1. 41681, 237. 615, 79. 5691,
33.1756,34.8772,33.7503,40.0537,0.0468644}
{0.250764,0.526959,0.75088,1.24455,1.41681,237.615,79.5691,
33.1756,34.8772,33.7503,40.0537,0.0468644}
{0.250764,0.526959,0.75088,1.24455,1.41681,237.615,79.5691,
33.1756,34.8772,33.7503,40.0537,0.0468644}
{0.250764,0.526959,0.75088,1.24455,1.41681,237.615,79.5691,
33.1756,34.8772,33.7503,40.0537,0.0468644}
{0.250764,0.526959,0.75088,1.24455,1.41681,237.615,79.5691,
33.1756,34.8772,33.7503,40.0537,0.0468644}
{0.263707,0.500701,0.721715,1.28121,1.42126,245.623,78.6553
,34.5749,35.2995,33.6475,38.4834,0.046347}
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{0. 263707, 0. 500701, 0. 721715, 1. 28121, 1. 42126, 245. 623, 78. 6553
,34.5749,35.2995,33.6475,38.4834,0.046347}
{0. 263707, 0. 500701, 0. 721715, 1. 28121, 1. 42126, 245. 623, 78. 6553
,34.5749,35.2995,33.6475,38.4834,0.046347}
{0. 263707, 0. 500701, 0. 721715, 1. 28121, 1. 42126, 245. 623, 78. 6553
,34.5749,35.2995,33.6475,38.4834,0.046347}
{0. 263707, 0. 500701, 0. 721715, 1. 28121, 1. 42126, 245. 623, 78. 6553
,34.5749,35.2995,33.6475,38.4834,0.046347}
{0.26258,0.506101,0.700213,1.26567,1.39091,251.932,74.7098,
37.1607,36.3779,30.5029,37.7239,0.0458202}
{0.257581,0.50856,0.706508,1.28737,1.39827,257.171,72.5289,
34.8305,35.6718,28.7054,38.2607,0.045108}
{0.262767,0.499935,0.703367,1.30487,1.44121,260.993,70.7219
,24.2106,31.5732,25.7524,40.5628,0.0445926}
{0. 262767, 0. 499935, 0. 703367, 1. 30487, 1. 44121, 260. 993, 70. 7219
,24.2106,31.5732,25.7524,40.5628,0.0445926}
{0. 262767, 0. 499935, 0. 703367, 1. 30487, 1. 44121, 260. 993, 70. 7219
,24.2106,31.5732,25.7524,40.5628,0.0445926}
{0.262767,0.499935,0.703367,1.30487,1.44121,260.993,70.7219
,24.2106,31.5732,25.7524,40.5628,0.0445926}
{0. 262767, 0. 499935, 0. 703367, 1. 30487, 1. 44121, 260. 993, 70. 7219
,24.2106,31.5732,25.7524,40.5628,0.0445926}
{0. 262767, 0. 499935, 0. 703367, 1. 30487, 1. 44121, 260. 993, 70. 7219
,24.2106,31.5732,25.7524,40.5628,0.0445926}
{0. 262767, 0. 499935, 0. 703367, 1. 30487, 1. 44121, 260. 993, 70. 7219
,24.2106,31.5732,25.7524,40.5628,0.0445926}
{0. 25778, 0. 505098, 0. 701505, 1. 30259, 1. 43124, 256. 834, 71. 2069,
27.6554,32.1395,27.7669,39.4803,0.044225}
{0. 25778, 0. 505098, 0. 701505, 1. 30259, 1. 43124, 256. 834, 71. 2069,
27.6554,32.1395,27.7669,39.4803,0.044225}
{0. 25778, 0. 505098, 0. 701505, 1. 30259, 1. 43124, 256. 834, 71. 2069,
27.6554,32.1395,27.7669,39.4803,0.044225}
75
{0.25778,0.505098,0.701505,1.30259,1.43124,256.834,71.2069,
27.6554,32.1395,27.7669,39.4803,0.044225}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237/
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.04262371
{0.257436,0.49706,0.686692,1.27825,1.4373,258.46,73.4372,28
76
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29.2206,32.2282,22.807,39.4542,0.0426237}
{0.257014,0.501918,0.674611,1.28554,1.40903,267.47,66.9127,
29..2206,32.2282,22.807,39.4542,0.0426237}
{0.257436,0.49706,0.686692,1.27825,1.4373,258.46,73.4372,28
.5185,30.6021,26.2144,40.0467,0.0425364}
{0.257436,0.49706,0.686692,1.27825,1.4373,258.46,73.4372,28
.5185,30.6021,26.2144,40.0467,0.0425364}
{0.238897,0.513469,0.702622,1.23204,1.44689,256.337,78.7969
,28.2836,29.0184,25.148,42.2688,0.041524}
{0.238897,0.513469,0.702622,1.23204,1.44689,256.337,78.7969
,28.2836,29.0184,25.148,42.2688,0.041524}
77
{0. 237695, 0. 518804, 0. 671366, 1. 19032, 1. 3894, 251. 715, 77. 1318,
38.252,31.4594,24.3302,38.9951,0.0401419}
{0. 229687, 0. 524609, 0. 670116, 1. 18195, 1. 41796, 253. 15, 76. 4631,
30.727,27.9083,21.4219,41.2665,0.0398154}
{0.23429,0.517425,0.684092,1.18096,1.41416,247.148,79.32,34
.9535,29.0971,24.6074,40.9644,0.0396665}
{0.23429,0.517425,0.684092,1.18096,1.41416,247.148,79.32,34
.9535,29.0971,24.6074,40.9644,0.0396665}
{0.229731,0.512676,0.672652,1.18344,1.41609,250.143,81.1045
,36.4801,29.168,24.4768,40.6036,0.03962}
{0. 229731, 0. 512676, 0. 672652, 1. 18344, 1. 41609, 250. 143, 81. 1045
,36.4801,29.168,24.4768,40.6036,0.03962}
{0. 23297, 0. 511146, 0. 617707, 1. 14587, 1. 36916, 253. 784, 74. 1137,
40.9961,29.2262,19.2592,38.1889,0.0378068}
{0.23297,0.511146,0.617707,1.14587,1.36916,253.784,74.1137,
40.9961,29.2262,19.2592,38.1889,0.0378068}
{0. 23297, 0. 511146, 0. 617707, 1. 14587, 1. 36916, 253. 784, 74. 1137,
40.9961,29.2262,19.2592,38.1889,0.0378068}
{0.23297,0.511146,0.617707,1.14587,1.36916,253.784,74.1137,
40.9961,29.2262,19.2592,38.1889,0.0378068}
{0.23297,0.511146,0.617707,1.14587,1.36916,253.784,74.1137,
40.9961,29.2262,19.2592,38.1889,0.0378068}
{0. 356444, 0. 822577, 1. 34913,2. 31252,2. 98369, 287. 075, 94. 9242,
59.6628,44.5176,30.462,45.799,0.0579231}
{0. 286683, 0. 743077, 1. 30586,2. 19906,2. 93302, 270. 144, 92. 9815,
60.4859,48.4838,35.8274,43.211,0.0523917}
{0.284202,0.729388,1.33023,2.13582,2.40913,270.142,92.9796,
60.4843,48.4825,35.8264,43.2095,0.058474}
{0. 216459, 0. 542905, 1. 10056, 1. 94259,2. 328, 251. 727, 86. 8389, 61
.9098,47.7887,32.0263,25.4833,0.043126}
{0. 181972, 0. 442113, 0. 845311, 1. 47267, 2. 15322, 242. 821, 78. 362,
61.005,47.2683,40.265,22.9433,0.03747871
78
{0. 14695, 0. 337169, 0. 582904, 0. 95779, 1. 44537, 234. 1, 68. 1373, 55
.1694,42.6518,32.2488,19.2305,0.0277599}
{0.12011,0.26782,0.443346,0.646658,0.892883,226.954,58.8343
,49.2466,38.5945,27.2086,16.8746,0.0206291}
{0. 0950424, 0. 208192, 0. 341205, 0. 491272, 0. 617853, 220. 676, 48.3
938,42.8374,36.1295,28.1633,21.5521,0.0180815}
{0.0883859,0.193007,0.317365,0.465097,0.640889,219.102,45.0
136,40.5918,35.5697,30.2027,28.4051,0.0174272}
{0. 0854971, 0.186568,0.308535,0.459051,0.646583,218.609,43.3
022,39.6415,35.8832,32.3294,29.2504,0.0173876}
10.,-5.16319,-3.71373,-
1.03061,3„0.,0.,806.291,1007.94,1276.85,0.,2.89621
{0.,-5.16319,-3.71373,-
1.03061,3„0„0.,806.291,1007.94,1276.85,0„2.8962}
10.,-5.16166,-3.71373,-
1.03061,3„0.,0.,806.291,1007.94,1276.85,0.,2.896421
10.,-5.16166,-3.71373,-
1.03061,3„0.,0.,806.291,1007.94,1276.85,0.,2.896421
{0.,-5.13717,-3.71373,-
1.03061,3„0„0.,806.291,1007.94,1276.85,0„2.90005}
{0.,-5.03014,-3.71373,-
1.03061,3„0„0.,806.291,1007.94,1276.85,0„2.91601}
{0.,-4.38831,-3.71373,-
1.03061,3„0„0.,806.291,1007.94,1276.85,0„3.01633}
10.,-4.38831,-3.71373,-
1.03061,3„0.,0.,806.291,1007.94,1276.85,0.,3.016331
{0.,-3.37165,-3.71373,-
1.03061,3„0„0.,806.291,1007.94,1276.85,0„3.52568}
{0.,-2.31765,-3.59472,-
1.03061,3„0„0.,806.291,1007.94,1276.85,0.,25.0378}
{0.241343,0.770011,1.88172,3„3„0.000344349,0.000347668,80
6.29,1007.93,1276.85,0.,1.34799}
{0.241343,0.770011,1.88172,3„3„0.000344349,0.000347668,80
6.29,1007.93,1276.85,0.,1.34799}
{1785.67,{0.0173875,{arg2-40.0853353,arg3-+0.186165,arg4-*0.3
07957,arg5-÷0.458314,arg6-*0.64555,arg7-+218.602,arg8-÷43.190
6,arg9-*39.5977,arg10-435.9248,arg11-*32.3445,arg12-+29.2819}
79
opt={1785.672',{0.017387540465247445',{arg2-+0.0853353341333
4127',arg3-+0.18616538388712472',arg4-+0.30795732355473754',
arg5-+0.4583143854064272 s ,arg6-*0.645550076680361s,arg7-+218.
60226499366627',arg8-443.19062768697064',arg9-+39.5976646980
12515',arg10-+35.9248352640499',arg11-432.344509517611264',a
rg12-+29.281883338641578'}})
{1785.67,{0.0173875,{arg2-40.0853353,arg3-+0.186165,arg4-+0.3
07957,arg5 -+0.458314,arg6-+0.64555,arg7-+218.602,arg8-+43.190
6,arg9 -+39.5977,arg10-+35.9248,arg11-+32.3445,arg12-+29.2819}
}}
NB=6;
tm=Flatten[{{0},Table[opt[[2,24,2]],{i,NB-
1}],{tf}}];Mb=Table[opt[[2,24,2]],{i,NB,2NB-1}];
60*tm
{0,5.12012,11.1699,18.4774,27.4989,38.733,60 tf}
Mb
{218.602,43.1906,39.5977,35.9248,32.3445,29.2819}
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